Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, June 24, 2025 /PRNewswire/ — Equity Insider News Commentary – Rising rates of cancer are going to come at a major cost, and it's looking more and more like the solution is going to have to come from the private sector. Recent reports suggest the U.S. government may slash National Cancer Institute (NCI) funding by nearly 40%, while Bloomberg reports growing concern over affordability and access to cancer drugs whose prices are rising sharply. From Wall Street's point of view, the focus needs to shift towards up-and-coming treatments being developed by promising candidates, including from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Indaptus Therapeutics, Inc. (NASDAQ: INDP), Perspective Therapeutics, Inc. (NYSE-American: CATX), SELLAS Life Sciences Group, Inc. (NASDAQ: SLS), and Autolus Therapeutics plc (NASDAQ: AUTL).
Analysts at Nova One Advisor are currently projecting the global oncology drug market to hit US$366.24 billion by 2034, expanding at a 7.4% CAGR. Others are even more optimistic, with ResearchAndMarkets estimating the sector will reach US$866.1 billion by 2034, growing at a 10.8% CAGR, and Vision Research Reports anticipating the market will top US$903.81 billion by the same year, driven by accelerating demand for advanced diagnostics and treatments. All this points to an optimal timing period for breakout cancer stocks.
Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has entered a new chapter with the appointment of Jared Kelly as Chief Executive Officer and member of the Board. With a background in high-value biotech transactions and late-stage development strategy, Kelly brings experience that may help position the company for its next phase of clinical and corporate progress.
Prior to joining Oncolytics, Kelly was General Counsel at Ambrx Biopharma, where he played a key role in the company's $2 billion acquisition by Johnson & Johnson. He also advised a range of life sciences firms on partnerships, licensing, and M&A during his tenure at Kirkland & Ellis LLP and Lowenstein Sandler LLP. His arrival comes as Oncolytics continues advancing pelareorep, a viral-based immunotherapy being evaluated in combination with checkpoint inhibitors and other agents across multiple cancer indications.
'Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications. Importantly, the data show that pelareorep creates a robust immunologic response in difficult tumors and increases survival in a patient population where survival has historically evaded most patients,' said Jared Kelly, CEO of Oncolytics Biotech. 'With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy. I am excited to get to work accelerating development and unlocking significant value for stakeholders.'
Kelly's appointment appears aligned with a focused strategy: advancing pelareorep through late-stage development while maintaining capital efficiency and openness to potential partnerships. The company's lead program continues to generate data that support further investigation across several difficult-to-treat cancers.
Pelareorep already holds FDA Fast Track designation in two separate indications — metastatic pancreatic ductal adenocarcinoma (mPDAC) and HR+/HER2- metastatic breast cancer (mBC) — a distinction that highlights regulatory interest in its potential.
Across clinical studies, the viral-based immunotherapy has consistently shown signs of immune activation, combinability with checkpoint inhibitors and chemotherapy, and efficacy in heavily pretreated populations.
In mPDAC, a Phase 2 cohort from the trial has reported objective response rates (ORR) above 60% in tumor-evaluable patients, exceeding historical benchmarks for this indication. Additional analyses have noted extended two-year survival rates compared to previous benchmarks. In HR+/HER2- mBC, two randomized Phase 2 trials (IND-213 and BRACELET-1) observed overall survival trends that support continued clinical evaluation.
Elsewhere, a Phase 2 anal cancer cohort combining pelareorep with a checkpoint inhibitor demonstrated partial or complete response rates that exceeded historical control trials for checkpoint inhibitor monotherapy, suggesting potential utility beyond the company's lead programs.
'Mr. Kelly's vision and track record is an extraordinary fit with the standout clinical data pelareorep has generated to date,' said Wayne Pisano, Chair of the Board and outgoing Interim CEO of Oncolytics. 'We believe Mr. Kelly's well-documented ability to prioritize clinical program development, execute successful financings, and attract the attention of large industry peers will help maximize Oncolytics' potential to deliver transformative outcomes for patients and exceptional value for investors.'
Kelly's compensation framework includes equity-based awards and performance-linked incentives tied to future financings and strategic outcomes. The structure is designed to align leadership priorities with long-term shareholder value while reinforcing a disciplined approach to capital and partnership development.
As multiple cohorts advance within the GOBLET study — including those in pancreatic and anal cancers backed by external funding and regulatory support — Oncolytics appears positioned to continue its progress with a blend of clinical momentum, financial flexibility, and sharpened strategic direction.
Prior to Kelly's appointment, Oncolytics presented new data from its GOBLET trial at the 2025 ASCO Annual Meeting, highlighting pelareorep's ability to stimulate both innate and adaptive immune responses in metastatic pancreatic cancer. With fresh clinical insights and new leadership in place, the company appears positioned to advance both its scientific and strategic priorities in tandem.
CONTINUED… Read this and more news for Oncolytics Biotech at: https://equity-insider.com/2025/03/18/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/
In other recent industry developments and happenings in the market include:
Indaptus Therapeutics, Inc. (NASDAQ: INDP) recently initiated dosing in a Phase 1b/2 study arm testing its lead candidate Decoy20 with PD-1 inhibitor tislelizumab in advanced solid tumors.
'This is an important milestone in our clinical development,' said Jeffrey Meckler, CEO of Indaptus. 'We have long believed the Decoy platform has the potential to be a game-changing approach to treating solid tumors.'
The combination is being evaluated in patients previously treated with checkpoint inhibitors or with tumor types typically unresponsive to immunotherapy. Early preclinical findings showed Decoy20 could synergize with PD-1 blockade to activate stronger anti-tumor immunity. The trial will monitor safety and preliminary signals of efficacy before broader enrollment.
Perspective Therapeutics, Inc. (NYSE-American: CATX) has recently opened enrollment for Cohort 3 of its Phase 1/2a trial testing [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor 2 (SSTR2)-positive neuroendocrine tumors.
'We are excited to start exploring a higher dose level of VMT-α-NET after successfully completing an interaction with the FDA that was agreed prior to commencement of this trial,' commented Markus Puhlmann, Chief Medical Officer of Perspective. 'We are encouraged by the overall clinical profile observed at the second dose level of VMT-α-NET—including evidence of anti-tumor activity and primarily low-grade adverse events—and we believe it is important to assess whether a higher dose could further improve the therapeutic profile. Meanwhile, we remain committed to engaging with the FDA to evaluate the clinical utility of dosimetry estimates and analyses in the development of our proprietary RPTs.'
The newly approved dose level represents a 20% increase over the previous cohort and will be evaluated for safety and early signals of efficacy. Interim results presented at American Society of Clinical Oncology (ASCO) Annual Meeting and Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting showed evidence of anti-tumor activity and favorable tolerability at lower doses. The company expects to submit additional clinical updates in the second half of 2025 following extended patient follow-up.
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) recently presented new preclinical data at the 2025 ASCO Annual Meeting showing that its CDK9 inhibitor SLS009 demonstrated potent activity in ASXL1-mutated colorectal cancer cell lines.
'These results provide strong rationale for continued advancement of SLS009 as a potential treatment for ASXL1-mutated cancers,' said Dr. Dragan Cicic, Senior Vice President, Chief Development Officer at SELLAS. 'The ability to selectively target ASXL1-driven tumors at concentrations well below the known safety threshold opens the door for tolerable and effective therapy. Based on the findings, we believe that ASXL1 mutation status could serve as a potential biomarker for response to SLS009 inhibition, which may allow us to further refine patient selection and improve outcomes. We look forward to presenting these results at ASCO.'
In the study, 75% of lines with ASXL1 frameshift mutations responded at low nanomolar concentrations, while no response was observed in wild-type lines. These findings suggest that ASXL1 mutation status may serve as a potential biomarker for patient selection.
Autolus Therapeutics plc (NASDAQ: AUTL) has released updated results from its FELIX study, showing that obe-cel, a next-generation CAR T cell therapy, may provide long-term remission for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). With a median follow-up of nearly 33 months, more than 50% of patients were still in remission at 24 months, and 38% had not needed any additional therapy.
'Obe-cel's durability of response without any subsequent therapy in two out of every five responders is a key factor leading the transformation of therapy for adult r/r B-ALL patients. At a median follow up of 33 months, we are encouraged to see a continuation of the long-term plateau we observed at the last data cut,' said Dr. Christian Itin, CEO of Autolus. 'A well-tolerated, effective, durable treatment option for ALL patients who often have a poor prognosis and have had multiple prior treatments is of significant clinical benefit.'
The data suggested obe-cel could serve as a standalone option for some patients, reducing the need for transplants or further treatment. The company also reported a strong safety profile and plans to continue advancing obe-cel as a potential cornerstone in adult B-ALL care.
Source: https://equity-insider.com/2025/03/18/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/
CONTACT:
Equity Insider info@equity-insider.com(604) 265-2873
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ('MIQ'). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Video – https://www.youtube.com/watch?v=BKIelfug7kwPhoto – https://mma.prnewswire.com/media/2717969/Pelareorep_Facts.jpgLogo – https://mma.prnewswire.com/media/2644233/5385655/Equity_Insider_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/wall-street-eyes-breakout-cancer-therapies-amid-soaring-drug-prices-302489986.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
2 hours ago
- The Star
Japan tariff negotiator held in-depth talks with Lutnick, Japanese government says
(From right) Japan's Economic Revitalisation Minister Ryosei Akazawa poses with US Treasury Secretary Scott Bessent, Commerce Secretary Howard Lutnick and US Trade Representative Jamieson Greer in Washington on May 1. - Photo: AFP TOKYO/BRIDGEWATER, New Jersey, (Japan/US): Japan's tariff negotiator Ryosei Akazawa held "in-depth exchanges" over the phone with US Commerce Secretary Howard Lutnick on Thursday (July 3) and Saturday (July 5), the Japanese government said. A pause on a 24% reciprocal tariff on imports from Japan expires on July 9, although US President Donald Trump has suggested the rate could be even higher. The Japanese government also said in a statement that it intends to continue actively coordinating with the United States' side on the matter, as it worked to avert higher tariffs. The White House declined to comment on the report, referring only to Trump's recent comments on Japan. Trump this week hammered Japan over what he said was Tokyo's reluctance to import US-grown rice, and accusing Japan of engaging in "unfair" autos trade. Japan has in fact imported historically high volumes of US rice in recent months as domestically grown rice has skyrocketed in price since last year. It was unclear if Trump would make good his pledge to skip further trade negotiations with Japan and send it a letter with a specific tariff rate, on top of the 10% already in effect on most trading partners. On Friday he said he had signed letters to 12 countries and they would be going out on Monday, but did not identify them. He expressed doubt that a deal could be reached with Japan on Tuesday, and suggested he could impose a tariff of 30% or 35% on imports from Japan - well above the 24% tariff rate he announced on April 2. Japanese Prime Minster Shigeru Ishiba on Wednesday said he was determined to protect his country's national interests as trade negotiations with the United States struggled, noting that his country was the largest investor in the United States. Tokyo has yet to secure a trade deal after nearly three months of negotiations as it scrambles to find ways to get Washington to exempt Japan's automakers from 25% automobile industry-specific tariffs, which are hurting the country's manufacturing sector. - Reuters
The Star
3 hours ago
- The Star
Is Mamdani a turning point for US politics?
ZOHRAN Mamdani recently won the Democratic primary race for Mayor of New York, making him likely to be the next leader of America's largest city. Mamdani beat out the establishment candidate and front runner, former New York governor Andrew Cuomo, by a considerable margin – securing 56% of the final vote to Cuomo's 44%. Three interesting issues surround this upset – issues which have wider implications for politics in America as a whole: the role of money in the election, Mamdani's position on the progressive left of the mainstream establishment of the Democratic party, and how the Israel-Palestine issue was a factor in the elections. In terms of independent expenditure, defined by Wikipedia as campaign communication that is not made in cooperation or consultation a candidate, Mamdani received about US$1mil (RM4.2mil). Cuomo on the other hand, received about US$16mil. This vast difference called to mind the difference in money raised in the last US presidential elections by Kamala Harris and Donald Trump: US$2.9bil for Harris, versus only US$1.8bil for Trump. These two instances point to a clearly emerging truth: money alone cannot guarantee the result of an election. This is counterintuitive on more than one level. We have an image of billionaires working to buy elections and politicians for their own advantage, and the election of Trump most certainly appears to have benefited these billionaires – especially in terms of recent tax cuts that seem made just for them. That said, the influence of money does not seem to be a cut and dry matter where the campaign with more money automatically wins. One takeaway from this is that future campaigns should pay attention to just how far the right messaging can go, when told effectively. Mamdani's campaign featured a laser focus on the issue of affordability in New York City that obviously resonated very well with the electorate. His campaign also employed simple but effective social media strategies – strategies that can be executed at more affordable (but usually not zero) cost, if you engage the right people. In an era where it's easy to think that throwing money into a campaign can put anyone across the finish line, it's refreshing to be reminded that the candidate, their message, and their campaign strategy can still prevail over much better funded candidates. When it comes to Mamdani's messaging, positioning, and policies, it is clear that Mamdani is more aligned with the likes of Bernie Sanders, and Alexandria Ocasio-Cortez (popularly known as AOC) and their further left, progressive, some might say 'socialist' or 'radical' leanings. These terms are sometimes used in relation to what are considered more old guard, centrist, establishment Democrats like Kamala Harris, Joe Biden, Hillary Clinton, Andrew Cuomo, and the like. Some view the latter as barely distinguishable from other establishment politicians on the other side of the aisle – serving larger corporate interests and special interest lobbies, and being out of touch with every day citizens. Arguably, this is how Republican voters also saw the mainstream, centrist Republicans of yore. Disaffection with this group led people first to the Tea Party Movement, and then even further right into the arms of Trump. The sentiment seemed to be that 'politics as usual' was just about the worst thing possible, and had long, long ago stopped serving the interests of normal Americans. Anger, resentment, and hatred against the established political class seems to have led many Americans to vote for whoever was 'not like the rest'. For those who leaned to the right, that became Trump. For those on the left, it meant people like Sanders, AOC, and now, Mamdani. Historian Jon Meacham recently said in an interview on the Daily Show that when a pendulum swings far to one end, it does not then stop in the centre, but swings further to the other side. Using this analogy, he speculated that a President Trump could pave the way in the future for a President AOC. Nobody knows whether such a thing would happen, but Mamdani's election may be the latest sign that people respond well to mavericks who display a clear willingness to break decisively away from an establishment perceived to be stuck in the mud. Another interesting factor in Mamdani's victory was his support for the Palestinian cause. The influence of the Zionist lobby in American politics is nearly a thing of legend. This lobby is represented most visibly in the American Israeli Public Affairs Committee (Aipac). Aipac has been known to campaign vigorously, with millions upon millions of dollars, to bring down any candidate (whether Democrat or Republican) who refuses to support Israel vigorously. In recent decades, they have been extremely successful. In the primary that Mamdani won, one memorable debate had the moderator ask the candidates a tellingly odd little question: If you become Mayor, which is the first foreign country you would visit? Every single one of the other candidates, including Cuomo, answered this question that was clearly planted as some sort of Aipac litmus test, loudly and without hesitation: 'Israel' – just like anyone who felt they lived and died on Aipac's support. Mamdani, however, said that he would stay right here in NYC, and that if he wanted to meet his Jewish constituents, he would happily do so in the synagogues and Jewish community centres right there in New York. The influence of Aipac is glaringly visible in debates like these. Politicians from either side of the aisle are always extremely guarded at best, when asked about anything to do with Israel or Palestine – always fearful of offending Aipac and its well-funded war machine. Mamdani expressed no such fear. He decided he would choose to be on the side of morality and history, instead of bow to Aipac. Politicians in the past have often been fearful of doing so, fearing it would lead to political suicide. Mamdani however stood up for what he believed in, and it would appear that voters responded – and by considerable margins. Other politicians should stand up and take note. The momentum in global support for the Palestinian cause is reaching unprecedented heights, and public opinion has shifted strongly in our social media world where the evidence is always there to see, clear as day – even as governments all around the world lag behind painfully slowly. Mamdani's bravery may be a turning point in that trend, and it comes not a moment too soon. As a brief aside, many Malaysians rejoiced at seeing a Muslim American do so well in American politics, and they are right to do so. In the same breath however, it may be useful to remember that the victory of a candidate from a minority background is something that should be celebrated, no matter what country they are in. Given all the troubles and challenges America is facing, having one decent man win a mayoral race will not be enough to turn the tide. But there is a chance, however small, that this victory may be the optimistic beginning of a journey of hope in the United States. Nathaniel Tan is a strategic communications consultant who can be reached at nat@ The views expressed here are solely the writer's own.
Malaysian Reserve
3 hours ago
- Malaysian Reserve
Sarawak key to ASEAN's green energy push
KUALA LUMPUR — The Sarawak-linked segment of the ASEAN Power Grid (APG) is shaping up to be a crucial enabler of regional decarbonisation efforts, supplying low-carbon hydropower to displace fossil fuel generation across Southeast Asia, said an expert. Prime Minister Datuk Seri Anwar Ibrahim reportedly said that Sarawak has the potential to become the main energy hub for Malaysia and ASEAN. The state could also play a key role in the APG initiative with its rich energy resources, including hydropower, gas and hydrogen. Trung Ghi, Arthur D. Little Southeast Asia partner and head of energy, utilities, and resources practice, said the tripartite cooperation of this scale strengthened regulatory alignment and accelerated institutional readiness. The move comes as Sarawak eyes a nearly threefold increase in renewable energy capacity to 15 gigawatts (GW) by 2035, positioning the state as a regional energy anchor. According to Sarawak Energy's 2035 Strategic Plan, this expansion includes continued hydropower development, solar scale-up, and hydrogen deployment. 'The 15GW target is ambitious but feasible with the right enablers. Continued hydropower development, solar scale-up and hydrogen deployment will be critical. If realised, it would significantly boost Sarawak's export capacity while enhancing domestic energy security,' Trung told Bernama in a written interview recently. Malaysia is currently exploring two cross-border transmission routes – one overland via Peninsular Malaysia and another via a direct undersea cable to Singapore. Trung said the route that secures financing, permits and offtake agreements first is likely to move ahead. 'Cost-efficiency and geopolitical alignment are key considerations. A route through Peninsular Malaysia may be quicker and cheaper, while direct access to Singapore's premium market could offer higher commercial returns,' he added. However, executing such projects across multiple jurisdictions remains complex, he said. Land acquisition, environmental clearances, maritime regulations and harmonisation of grid codes are just some of the challenges ahead. 'Continued coordination among governments, regulators and industry players will be critical,' stressed Trung. Despite heavy reliance on fossil fuels across ASEAN, the regional power grid offers a long-term structural solution for emissions reduction, if infrastructure, regulation and markets are effectively aligned. In May, ASEAN Secretary-General Dr Kao Kim Hourn reportedly said the APG vision requires an estimated investment of US$764 billion (US$1 = RM4.23) for power generation and transmission infrastructure. 'Mobilising this level of capital will demand a stable regulatory environment and clear project pipelines,' Trung said. To support this, the ASEAN Power Grid Finance Facility Framework, jointly developed by the Asian Development Bank (ADB) and the World Bank, is expected to be launched at the ASEAN Summit in October 2025. 'The ADB has signalled its willingness to commit up to US$10 billion for cross-border energy infrastructure,' Trung added. Looking ahead, Trung reckons Sarawak's success could offer a blueprint for other sub-regional linkages, such as Thailand–Laos–Cambodia and Indonesia–Brunei–Peninsular Malaysia. 'While each region has different dynamics, the idea of linking surplus generation to high-demand centres through cross-border infrastructure can be adapted and replicated,' he added. Trung also noted that ASEAN could draw lessons from Europe's ENTSO-E network and China's Belt and Road Energy Corridor, particularly in terms of central coordination, technical harmonisation and investor confidence. Climate finance instruments, including green bonds, blended finance and carbon-linked mechanisms, are also expected to play a growing role in bankrolling the region's clean energy transition, according to Trung. 'Green bonds can reduce financing costs for infrastructure, while blended finance and carbon credits help address early-stage risks and monetise emissions reductions,' he said. As the APG gains traction, he said Sarawak's hydropower-driven export model could play a defining role in transforming the region's energy landscape, marking a turning point in the pursuit of sustainable growth and energy resilience. — BERNAMA
